Two years after the acquisition of Matrix by Agfa-Gevaert of Belgium(SCAN 12/14/88), medical imaging film and equipment sales arerising for the Agfa Matrix division of Agfa. The company's annualU.S. medical film sales have risen at a rate about twice the
Two years after the acquisition of Matrix by Agfa-Gevaert of Belgium(SCAN 12/14/88), medical imaging film and equipment sales arerising for the Agfa Matrix division of Agfa. The company's annualU.S. medical film sales have risen at a rate about twice the 6%industry average over the past two years. This growth has occurredeven though Matrix--an electronic imaging pioneer--did not bringfilm products to the new company, said Agfa Matrix president GeraldWagner.
Although the market for CRT-based multiformat cameras has saggedunder the onslaught of laser printers, Agfa Matrix has benefitedfrom the large installed base of Matrix cameras in U.S. hospitals,he said. The company sells both laser and CRT-based cameras.
Agfa Matrix could benefit significantly over the long run bykeeping its hand in the CRT camera field. As technology improvesand demand for lower cost distributed units grows, so might thedemand for CRT cameras, he said.
Matrix was predominantly an OEM supplier of electronic medicalimaging equipment. Agfa-Gevaert Rex, on the other hand, had asales and distribution force in the U.S. to handle its film andfilm-handling equipment products but was looking for ways to grow.Agfa Matrix now sells the combined medical imaging product linedirectly to hospitals while maintaining the Matrix OEM sales andservice business, Wagner said. The new unit also manufacturesmedical imaging products for worldwide distribution by Agfa.
Agfa Matrix sales and marketing functions have been consolidatedinto Agfa headquarters in Ridgefield Park, NJ, while technicaland service functions are based at the Matrix facility in Orangeburg,NY. The medical imaging business has been enhanced by its tiesto other business units within Agfa and Germany's Bayer Group,Agfa's parent company, Wagner said.
"As part of the Bayer family, we can offer more attractivepackages to hospital groups," he said.
Rather than tacking Matrix onto Agfa's worldwide medical imagingbusiness, Agfa Matrix was formed into a division of a reconstitutedAgfa Corp. in the U.S. Agfa in the U.S. has about $1 billion inannual revenues and employs 5000 people. It is a subsidiary ofBayer USA.
Although Agfa reports to Bayer in the U.S., the vendor continuesto coordinate global medical imaging efforts. Wagner is also managingdirector of equipment technology for the technical imaging businessunit of Agfa's worldwide business. He heads up both R&D andmanufacturing of medical imaging systems and coordinates a totalmedical R&D staff of over 300 individuals, he said.
According to Wagner, several factors may have combined to increaseAgfa Matrix sales more than the sum of the two previous businesses:
THERE IS LIFE IN THE CRT MARKET, despite competition from lasercameras, Wagner said. Laser devices are glamorous but expensive.They are valuable to an imaging department--particularly in high-throughputsituations--but are not the only hard-copy answer. Hospitals shouldbe free to use the technology that best meets their own needs,he said.
Similar technologies, such as photocopiers and computers, haveevolved from expensive centralized devices to smaller personalizedunits. Medical imaging cameras could follow this trend, as hospitalssearch for convenience and low prices, Wagner said.
CRT devices also have some intrinsic advantages over lasercameras, which could be enhanced through product development efforts,he said.
"It seems more reliable to deflect an electron beam ina vacuum without any moving parts rather than a light beam byuse of high-speed mirrors or other mechanical devices. Also, youdon't have dust in a CRT," he said.
The trend to decentralized equipment is a factor in the filmprocessing field as well, where Agfa developed a compact versionof its Curix processor. Demand for the smaller unit has been briskas the number of decentralized imaging sites increases in fieldssuch as mammography, he said.
MORE MULTI-YEAR BINDING CONTRACTS are being signed between hospitalsand film/camera vendors. This could be either a good or bad trend,Wagner noted. Discounting of equipment in order to lock in yearsof film sales might be disadvantageous to a hospital if a betterfilm alternative comes along later. Cooperative approaches tohospital imaging needs, however, can benefit both the vendor andcustomer, he said.
"Binding is good as long as it is accompanied by jointefforts. A system supplier might agree to provide optimum imagequality (at a particular site) or help with management and logistics.Special rates on service might be arranged in exchange for long-termcontracts. This (type of cooperation) makes sense. It createsa feeling of co-ownership," he said.
Cooperation between hospitals and vendors can also help reduceproduct costs over the long run, Wagner said. Vendors requirehigher profit margins when the business is risky. If sales canbe made more predictable over certain time periods, vendors maytrim margins and reduce the price to their customers, he said.
BRIEFLY NOTED:
Medstone suspended its gallstone lithotripsy research programlast year due to delays obtaining Food and Drug Administrationmarketing approval and sagging prospects for the biliary blastermarket (SCAN 12/12/90).
"Initial projects in proprietary biologicals and smallmolecule pharmaceuticals are linked to Medstone's customer baseof urologists. Our lithotripters treat over 6000 cases of renaldisease per year, and there are attractive medical and economicopportunities in new drug therapies for chronic urologic disease,"said chairman Errol Payne.
Victoreen's European sales have helped the company maintaina 25% annual growth rate since 1989, said president Michael J.Kirchoff. The firm's enhanced service capability will help Victoreentake advantage of business opportunities in a unified EuropeanCommunity, he said.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.